Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
- PMID: 32584593
- PMCID: PMC7322811
- DOI: 10.7326/L20-0887
Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
Comment on
-
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.Ann Intern Med. 2020 Aug 4;173(3):195-203. doi: 10.7326/M20-1515. Epub 2020 May 15. Ann Intern Med. 2020. Update in: Ann Intern Med. 2021 Feb;174(2):W25-W29. doi: 10.7326/L20-1446. Update in: Ann Intern Med. 2021 Jun;174(6):W54-W55. doi: 10.7326/L21-0223. PMID: 32422062 Free PMC article. Updated.
References
-
- Chen Y, Yang D, Cheng B, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020;43:1399-1407. [PMID: 32409498] doi:10.2337/dc20-0660. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous